Semin intervent Radiol 2011; 28(2): 142-146
DOI: 10.1055/s-0031-1280652
© Thieme Medical Publishers

Hepatic Artery Dissection in a Patient on Bevacizumab Resulting in Pseudoaneurysm Formation

Daniel B. Brown1
  • 1Division of Interventional Radiology and the Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania
Further Information

Publication History

Publication Date:
16 June 2011 (online)

ABSTRACT

Interventional radiologists are frequently encountering patients with colorectal cancer that are being treated with bevacizumab. This therapeutic agent is associated with a potentially increased risk of adverse events when invasive procedures are performed while patients are on therapy. The current case report reviews a complication related to planning angiography for radioembolization with Yttrium-90 microspheres in an individual on bevacizumab and subsequent management of the patient.

REFERENCES

  • 1 Gordon C R, Rojavin Y, Patel M et al.. A review on bevacizumab and surgical wound healing: an important warning to all surgeons.  Ann Plast Surg. 2009;  62 (6) 707-709
  • 2 Kemeny M M. How many patients and how many complications does it take to decide if a drug is safe to use before surgery?.  J Clin Oncol. 2009;  27 (11) 1917-1918, author reply 1918
  • 3 Kesmodel S B, Ellis L M, Lin E et al.. Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases.  J Clin Oncol. 2008;  26 (32) 5254-5260
  • 4 Petrelli N J. Bevacizumab and postoperative complications after hepatic surgery for colorectal metastases.  J Clin Oncol. 2009;  27 (11) 1917, author reply 1918
  • 5 Scappaticci F A, Fehrenbacher L, Cartwright T et al.. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab.  J Surg Oncol. 2005;  91 (3) 173-180
  • 6 Cheon E C, Small Jr W, Strouch M J et al.. The effects of bevacizumab on postoperative complications in patients undergoing colorectal and pancreatic cancer resection.  J Surg Oncol. 2010;  102 (5) 539-542
  • 7 Hurwitz H, Fehrenbacher L, Novotny W et al.. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.  N Engl J Med. 2004;  350 (23) 2335-2342
  • 8 Kabbinavar F F, Schulz J, McCleod M et al.. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.  J Clin Oncol. 2005;  23 (16) 3697-3705
  • 9 Erinjeri J P, Fong A J, Kemeny N E, Brown K T, Getrajdman G I, Solomon S B. Timing of administration of bevacizumab chemotherapy affects wound healing after chest wall port placement.  Cancer. 2011;  117 (6) 1296-1301
  • 10 Brown D B, Cardella J F, Sacks D et al.. Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy.  J Vasc Interv Radiol. 2009;  20 (7, Suppl) 219-226
  • 11 Ahn J, Trost D W, Mitty H A, Sos T A. Pseudoaneurysm formation after catheter dissection of the common hepatic artery: report of two cases.  Am J Gastroenterol. 1997;  92 (4) 696-699

Daniel B BrownM.D. 

Division of Interventional Radiology and the Kimmel Cancer Center, Thomas Jefferson University

132 South 10th Street, Suite 766, Philadelphia, PA 19107

Email: daniel.brown@jefferson.edu